10-Q: Masimo Q2 Sees Healthcare Growth Amidst Divestiture & Legal Battles

Masimo Corporation reports increased revenue and gross profit in its continuing healthcare operations, while navigating a significant loss from discontinued non-healthcare business due to impairment charges and ongoing complex litigations.

Summary

• Revenue from continuing operations (healthcare) increased by 7.9% to $370.9 million for the three months ended June 28, 2025, compared to $343.9 million in the prior year.
• Gross profit margin for continuing operations improved to 62.9% for the three months ended June 28, 2025, up from 60.3% in the prior year, driven by operational efficiencies and product cost reductions.
• Net income from continuing operations rose to $44.9 million for the three months ended June 28, 2025, from $24.8 million in the same period last year.
• The non-healthcare consumer business, now classified as discontinued operations, incurred a net loss of $211.5 million for the six months ended June 28, 2025, primarily due to approximately $295.0 million in intangible asset impairment charges.
• A definitive agreement was signed on May 6, 2025, to sell the non-healthcare business to Harman International Industries (a Samsung subsidiary) for $350 million in cash, with closing expected by the end of 2025.
• A cybersecurity incident on April 27, 2025, temporarily impacted manufacturing and order processing, incurring $4.5 million in SG&A expenses (net of $1.0 million insurance reimbursement), but operations returned to normal by June 28, 2025.
• The company is involved in multiple significant legal proceedings, including patent infringement and trade secret cases against Apple, shareholder class action and derivative lawsuits, and investigations by the Department of Justice and SEC related to product recalls and accounting practices.
• Joe Kiani's employment as former Chairman and CEO was terminated for cause on October 24, 2024, leading to ongoing litigation regarding his severance and other claims.
• New executive appointments include Catherine Szyman as CEO, Elisabeth Hellmann as Chief Human Resources Officer, and Tim Benner as Chief Marketing and Strategy Officer.

Sentiment

Score: 6

Explanation: The core healthcare business shows strong operational improvements and growth, and the planned divestiture is a positive strategic move. However, the significant impairment charges from discontinued operations and the extensive, costly ongoing legal battles, coupled with regulatory investigations, introduce considerable uncertainty and financial burden, balancing out the positive operational performance.

Positives

• Continuing healthcare operations demonstrated strong revenue growth, increasing 7.9% for the quarter and 8.7% for the six-month period.
• Gross profit margin for the healthcare segment improved significantly to 62.9% from 60.3% in the prior quarter, reflecting operational efficiencies and product cost reductions.
• Net income from continuing operations more than doubled for the quarter, reaching $44.9 million, indicating improved profitability in the core business.
• Research and development expenses decreased by 23.5% for the quarter and 16.9% for the six-month period, suggesting cost optimization in R&D.
• A definitive agreement to divest the non-healthcare business for $350 million provides a clear path to streamline operations and focus on the core healthcare segment.
• The company successfully returned all manufacturing operations to normal following the cybersecurity incident by June 28, 2025.
• A settlement in principle has been reached in the Sergio Vazquez Securities Class Action, potentially resolving a significant legal overhang.
• The jury in Apple's patent claims against Masimo W1 found that current product offerings do not infringe any Apple patents, a favorable outcome for ongoing products.

Negatives

• The non-healthcare discontinued operations reported a substantial net loss of $211.5 million for the six months ended June 28, 2025, primarily due to $295.0 million in intangible asset impairment charges.
• Selling, general and administrative expenses increased by 10.0% for the quarter, driven by higher legal and professional fees and costs related to the cybersecurity incident.
• The company incurred $1.9 million in incremental tariffs, which partially offset gross profit improvements.
• Ongoing and complex litigation with Apple, including a pending jury trial on patent infringement claims, continues to pose a significant legal and financial burden.
• The termination of former CEO Joe Kiani's employment for cause has resulted in multiple lawsuits and claims, including a potential $100 million claim under the California Private Attorney General Act.
• The company is under investigation by the Department of Justice and the SEC regarding a product recall delay and alleged accounting irregularities/internal control deficiencies, which could lead to material fines or liabilities.
• The Cross-Licensing Agreement with Willow Laboratories, Inc. now requires increased minimum annual royalties of $15.0 million due to the change in control related to Mr. Kiani's termination.

Risks

• Changes in U.S. trade policies and tariffs, particularly on components sourced from Mexico, China, and Malaysia, could increase costs or decrease demand for products.
• Reductions in FDA workforce (e.g., 3,500 layoffs in 2025) may disrupt timely regulatory reviews and approvals of new medical devices, impacting product pipeline and commercial viability.
• Estimated $1 trillion in cuts to Medicaid spending from the One Big Beautiful Bill Act could reduce hospital revenues and adversely impact sensor utilization and order patterns.
• Ongoing and future litigation, including those with Apple, former CEO Joe Kiani, and shareholder actions, could result in significant financial losses, injunctive relief, or reputational damage.
• Investigations by the Department of Justice and SEC related to product recalls and alleged accounting irregularities could lead to material fines, penalties, or other liabilities.
• The company's ability to successfully complete the proposed sale of its non-healthcare business is subject to conditions and regulatory approvals, and there is no guarantee of timely closing or maintaining third-party relationships.
• Exposure to supply chain volatility, inflationary pressures, interest rate volatility, rising energy costs, and foreign currency fluctuations could adversely affect financial performance.
• The business is influenced by seasonality, with historically lower healthcare revenues in the third fiscal quarter due to summer vacation schedules and fewer elective procedures.
• The company's ability to sell healthcare products to U.S. hospitals depends on relationships with Group Purchasing Organizations (GPOs), and changes in these relationships could impact revenue.

Future Outlook

The company anticipates continued growth in its healthcare business, driven by innovation and strategic focus. It expects to complete the divestiture of its non-healthcare business by the end of 2025, subject to regulatory approvals. The company is actively working to mitigate the impact of tariffs and is assessing the effects of recent U.S. tax law changes, including potential Medicaid spending cuts. Future cash requirements include investments in infrastructure growth, potential acquisitions, stock repurchases, and ongoing legal defense of intellectual property. The company believes existing cash, credit facility, and cash from operations will be sufficient for the next 12 months, but may seek additional financing if needed.

Management Comments

• We aim to accelerate our growth strategies by continuously innovating and prioritizing patient care with a lens toward value-creation initiatives.
• We continue to be optimistic about our long-term growth and prospects, despite experiencing volatility in our healthcare business.
• We are actively working to mitigate the operating profit impact of these tariffs with adjustments to our supply chain and manufacturing, as well as a significant amount of administrative effort to qualify our products for exemptions.
• We intend to vigorously pursue all of our claims against Apple and believe we have good and substantial defenses to Apple's claims.
• We are cooperating with the government and may expend significant financial and managerial resources in connection with responding to the subpoenas and investigative demand and any related investigation or any other future request for information.

Industry Context

The healthcare market remains highly competitive and dynamic, facing headwinds such as supply chain volatility, inflationary pressures, and interest rate fluctuations. Masimo's strategic realignment to refocus on profitability and divestiture of its non-healthcare consumer audio business aligns with a broader industry trend of companies streamlining operations to concentrate on core competencies and maximize shareholder returns. The impact of U.S. government policy changes, including FDA workforce reductions and potential Medicaid spending cuts, introduces regulatory uncertainty and could affect the medical device ecosystem. The ongoing global conflicts also present a minor, but monitored, risk to international business.

Comparison to Industry Standards

• Masimo's gross profit margin of 62.9% for its healthcare segment is competitive within the medical device industry, often exceeding the average for diversified healthcare companies, which can range from 50% to 70% depending on product mix and innovation.
• The increase in noninvasive technology boards and instruments shipped (63,100 for the quarter, 135,300 for six months) indicates strong product adoption and market penetration, comparable to growth seen by leading patient monitoring companies like Medtronic or Philips in their respective segments.
• The divestiture of the non-healthcare business for $350 million, while resulting in a significant impairment charge, is a strategic move to align with industry peers who focus on specialized, high-margin medical technology, similar to how GE Healthcare spun off its healthcare unit or Siemens Healthineers maintains a focused portfolio.
• The company's R&D spending decrease, while potentially a cost-saving measure, warrants close monitoring as industry leaders like Abbott Laboratories or Boston Scientific typically maintain robust R&D investments to drive innovation and competitive advantage.
• The ongoing legal disputes, particularly with Apple, are a unique and significant challenge, not typical for most medical device companies, but large tech companies often face complex IP litigation, which can be a substantial drain on resources, as seen with Qualcomm or Samsung.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing patent infringement, trade secret misappropriation, and inventorship claims against Apple Inc. in the U.S. District Court for the Central District of California, with a jury trial on patent infringement scheduled for November 4, 2025.
• U.S. International Trade Commission (ITC) found Apple violated Section 337, issuing a Limited Exclusion Order and Cease and Desist Order on infringing Apple Watches; Apple's appeal is pending.
• Apple filed complaints against Masimo W1 watch for patent infringement, with a jury finding that current Masimo products do not infringe Apple patents, but discontinued versions infringed two design patents, resulting in a $250 award to Apple; Masimo's counterclaims are pending.
• A putative class action complaint (Sergio Vazquez Securities Class Action) alleging federal securities law violations has reached a settlement in principle.
• Two purported stockholder derivative actions (Linda McClellan and Dianne Himmelberger) alleging breach of fiduciary duties by current and former executives/directors have been consolidated, with an amended complaint filed.
• The company received a subpoena from the Department of Justice (DOJ) and a civil investigative demand under the False Claims Act related to Rad-G and Rad-97 products and a recall delay.
• The company received a subpoena from the Securities and Exchange Commission (SEC) seeking documents related to alleged accounting irregularities and internal control deficiencies.
• Litigation filed by the company against former CEO Joe Kiani in Delaware Court of Chancery seeking declarations that his employment agreement provisions, including a $35 million cash payment and 2.7 million RSUs, are invalid and unenforceable.
• Former CEO Joe Kiani filed claims in California Superior Court seeking benefits from his employment termination for 'Good Reason' and intends to file claims under the California Private Attorney General Act for over $100 million.
• The company commenced litigation (RTW Litigation) against Joe Kiani and RTW Investments, LP, seeking disgorgement of short-swing profits under Section 16(b) of the Exchange Act.
• Willow Laboratories, Inc. filed an arbitration demand against the company alleging breach of the Cross-Licensing Agreement, seeking at least $2.75 million in damages and specific performance.

Related Party Transactions

• Cross-Licensing Agreement with Willow Laboratories, Inc. (Willow): Annual minimum royalty increased from $5.0 million to $15.0 million per year due to Joe Kiani's termination (change in control), plus a $2.5 million license fee for blood glucose monitoring technology. Royalty expenses to Willow were $4.9 million for the three months and $10.6 million for the six months ended June 28, 2025.
• Administrative Services Agreement with Willow: Terminated effective April 30, 2025.
• Lease Agreement with Willow: Expired December 31, 2024, and was not renewed; no lease income recognized in the current periods.
• Net amounts accrued and unpaid to Willow were approximately $2.9 million as of June 28, 2025.
• No cash contributions were made to the Masimo Foundation for Ethics, Innovation and Competition in Healthcare during the three and six months ended June 28, 2025; the company halted all payments as of Q3 2024.
• Marketing service agreement with Like Minded Media Ventures (LMMV), co-founded by Joe Kiani, was terminated in Q4 2024.
• Aircraft time share agreement with Joe Kiani was terminated upon his employment termination.
• The company received a $2.0 million payment from Politan Capital Management LP related to legal expenses for the six months ended June 28, 2025.
• Sales to Cardinal Health, Inc., where Michelle Brennan (Chairman of the Board) also serves as a director, were approximately $25.8 million for the three months and $57.6 million for the six months ended June 28, 2025. Amounts owed from Cardinal were approximately $17.4 million as of June 28, 2025.

Stakeholder Impact

• **Shareholders**: The planned divestiture of the non-healthcare business aims to enhance focus on the core healthcare segment, potentially improving long-term value. However, the significant impairment charges from the discontinued operations and ongoing legal disputes, particularly with the former CEO and Apple, create uncertainty and could impact share price volatility and investor confidence. The stock repurchase program may provide some support to share value.
• **Employees**: Management changes, including the appointment of a new CEO and other key executives, signal a shift in leadership and strategic direction. The strategic realignment initiative implemented in Q4 2024 could involve operational footprint optimization, potentially affecting employee roles or locations. The cybersecurity incident temporarily impacted operations, but the quick return to normal suggests resilience.
• **Customers**: The cybersecurity incident temporarily affected order processing and fulfillment, potentially causing delays for customers. The voluntary recall of Rad-G products and related DOJ investigation could impact customer trust and product perception. Continued innovation in healthcare products aims to improve patient outcomes and care, benefiting healthcare providers and patients.
• **Suppliers**: Efforts to mitigate tariff impacts, including evaluating alternative suppliers and vertical integration, could lead to changes in supplier relationships and sourcing strategies.
• **Creditors**: The company's liquidity position, with increased cash and working capital, along with available borrowing capacity under its Credit Facility, suggests a stable financial standing to meet its obligations. However, the financial impact of ongoing litigation and investigations remains a potential concern.

Next Steps

• Complete the sale of the non-healthcare business to Harman International Industries by the end of 2025, subject to regulatory approvals.
• Continue to assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements, particularly regarding Medicaid spending cuts.
• Vigorously pursue all claims against Apple and defend against Apple's claims, with a jury trial on patent infringement scheduled for November 4, 2025.
• Continue to cooperate with DOJ and SEC investigations related to product recalls and alleged accounting irregularities.
• Address the ongoing litigation with former CEO Joe Kiani and Willow Laboratories, Inc.
• Monitor and mitigate the impact of tariffs on supply chain and manufacturing costs, including evaluating alternative suppliers and vertical integration.

Key Dates

Recommendation

Masimo's core healthcare business shows promising growth and improved profitability, supported by strategic divestiture of the non-healthcare segment. This focus on the higher-margin healthcare segment is a positive long-term driver. However, the company faces significant near-term headwinds from substantial impairment charges related to the discontinued operations and a multitude of complex, high-stakes legal battles, including those with Apple, its former CEO, and regulatory bodies. These legal and regulatory uncertainties could lead to unpredictable financial outcomes and continued volatility. While the core business is strong, the ongoing litigations and investigations create a cloud of uncertainty that warrants a 'hold' recommendation until there is greater clarity on their resolution and financial impact.

Keywords

Healthcare technology, Patient monitoring, Medical devices, Pulse oximetry, SEC filing, 10-Q, Financial results, Corporate divestiture, Litigation, Cybersecurity, Corporate governance, Masimo, MASI